Pfizer Has a New Playbook for Reviving Sales—And It’s Starting to Pay Off
The drugmaker has revamped how it packages, promotes and sells certain medicines in an effort to overcome a postpandemic ...
Zacks Investment Research on MSN2d
Pfizer Is a Dirt-Cheap High-Yield Stock, But Is It a Buy?
Of late, pharmaceutical behemoth Pfizer Inc.’s PFE stock has struggled, but it remains a bargain with generous dividends. Its ...
Pfizer Is Now a High-Yield Bargain Stock
Pfizer's stock has recently struggled but remains a bargain with generous dividends. Is now a good time to invest in PFE?
Pfizer Is Trading As If It's 2009 Again
Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...
Pfizer created phone line for doctors, saw increase in Nurtec sales, WSJ says
After learning doctors weren’t prescrbing its migraine drug Nurtec because they assumed insurance coverage would be a hassle, the company ...
pharmaphorum3d
Pfizer offers $60m to settle prescriber kickback claims
The Department of Justice (DoJ) claims that Biohaven – before being acquired by Pfizer – paid "improper remuneration" to some Nurtec ODT (rimegepant) prescribers in the form of speaker fees ...
Healthcare Dive7d
Optum Rx says it will eliminate 10% of prior authorizations
The massive pharmacy benefit manager plans to stop requiring coverage reauthorizations for roughly 80 drugs used to treat ...
Wall Street Journal9d
Pfizer Has a New Playbook for Reviving Sales—and It’s Starting to Pay Off
Pfizer PFE0.34%increase; green up pointing triangle had a problem. Doctors weren’t prescribing its migraine drug Nurtec because they assumed insurance coverage would be too much of a hassle.